We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antiangiogenic Drug Blocks Breast Cancer Metastasis in Mouse Models

By LabMedica International staff writers
Posted on 24 Jun 2015
Print article
Image: Micrograph showing a lymph node invaded by ductal breast carcinoma and with extranodal extension of tumor. The dark purple (center) is lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is ductal breast carcinoma (Photo courtesy of Wikimedia Commons).
Image: Micrograph showing a lymph node invaded by ductal breast carcinoma and with extranodal extension of tumor. The dark purple (center) is lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is ductal breast carcinoma (Photo courtesy of Wikimedia Commons).
Cancer researchers have identified a potential drug target in preclinical studies that by being blocked prevented breast cancer metastasis in several mouse models.

Investigators at Lund University (Sweden) worked with multiple mouse models of breast cancer as well as analyzing tumor samples from 768 patients in a population-based, nested case-control study. Results were combined with breast cancer gene-expression data from The Cancer Genome Atlas (Bethesda, MD, USA), a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.

The combination of a computational biology approach with mechanism-based preclinical trials described in a paper published in the June 15, 2015, issue of the journal Cancer Research enabled the investigators to identify inhibitors of activin-like receptor kinase (ALK) 1 as effective agents for blocking formation of new blood vessels and metastasis in breast cancer. Pharmacologic targeting of ALK1 with the drug dalantercept provided long-term therapeutic benefit in mouse models of mammary carcinoma, accompanied by strikingly reduced metastatic colonization as a monotherapy or in combination with the chemotherapeutic drug docetaxel.

Dalantercept is a novel antiangiogenic agent, which is a soluble form of ALK1, and acts as a ligand trap for the bone morphogenetic proteins BMP 9 and BMP 10, inhibiting their interaction with ALK1.

Gene-expression analysis of breast cancer specimens from a population-based nested case–control study encompassing 768 subjects defined endothelial expression of ALK1 as an independent and highly specific indicator of metastatic potential. ALK1 expression correlated with the expression of well-known endothelial markers, and higher levels of ALK1 expression were an independent prognostic factor for poor survival in breast cancer patients.

Senior author Dr. Kristian Pietras, professor of molecular medicine at Lund University, said, "We are investigating the role of ALK1 protein expressed by endothelial cells in promoting metastatic dissemination from primary breast tumors. Our results suggest that the presence of high levels of ALK1 in the breast tumor vasculature is a prognostic biomarker for metastatic disease. Moreover, our work encourages clinical testing of drugs blocking ALK1 in breast cancer with prevention of metastatic dissemination as the primary outcome. We are currently performing therapeutic studies with dalantercept in models of breast cancer in order to pinpoint the precise therapeutic regimen and disease stage at which the treatment is the most effective."

Related Links:

Lund University
The Cancer Genome Atlas


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.